Research programme: immunotherapeutics - Nextera AS

Drug Profile

Research programme: immunotherapeutics - Nextera AS

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nextera
  • Class
  • Mechanism of Action HLA antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Crohn's disease; Haematological malignancies

Most Recent Events

  • 21 Sep 2015 Nextera AS and Janssen Biotech agree to conduct verification studies using Nextera's technology in Norway for Rheumatoid Arthritis
  • 21 Sep 2015 Early research in Crohn's disease in Norway (unspecified route)
  • 21 Sep 2015 Early research in Haematological malignancies in Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top